64
HIV Antiretroviral Therapy
Thursday, October 9, 2014: 2:00 PM-3:45 PM
Room: The Pennsylvania Convention Center: 107-AB
Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Health care workers, HIV clinicians, HIV specialists, Infection preventionists, Infectious diseases physicians, Members-in-training, Public health practitioners
Tracks: Adult ID, Epidemiology and Infection Control, Global ID, HIV-STD-TB
Moderators:
David Wohl, MD, University of North Carolina
and
Judith Aberg, MD, FIDSA, Icahn School of Medicine at Mount Sinai
Presentations:
2:00 PM
Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) Comparing Initial Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI)- versus Ritonavir Boosted Protease Inhibitor (PI/r)-based Anti-Retroviral Therapy (ART)
Álvaro H Borges, MD, MSc
;
Andreas Lundh, MD, MSc, PhD
;
Britta Tendal, PhD
;
Tania B Huedo-Medina, PhD
;
John a Bartlett, MD
;
Dominique Costagliola, PhD
;
Nathan Clumeck, MD
;
Eric S Daar, MD
;
Edwin Dejesus, MD, FACP. FIDSA
;
Patricia Echeverría, MD
;
Magnus Gisslén, MD, PhD
;
Miwako Honda, MD
;
Michael Hughes, Ph.D.
;
P Khabo, PhD
;
Stephanus Komati, MD, PhD
;
Princy N. Kumar, MD
;
Shahin Lockman, MD, MSc
;
Rodger Macarthur, MD
;
Franco Maggiolo, MD, PhD
;
Alberto Matteelli, MD
;
José M Miró, MD
;
Rebekah L Puls, MD, PhD
;
Sharon Riddler, MD, MPH
;
Paul Sax, MD, FIDSA
;
Juan Sierra-Madero, MD
;
Carlo Torti, MD
;
Jens Lundgren, MD, D.M.Sc., Professor
CME Credits:
ACPE Credits:
ACPE Number:
Disclosures:
D. Wohl,
Gilead: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient
Janssen: Scientific Advisor, Consulting fee
Merck: Grant Investigator, Grant recipient
ViiV: Grant Investigator, Grant recipient
J. Aberg,
Merck: Scientific Advisor, Consulting fee
Janssen: Scientific Advisor, Consulting fee
AbbVie: Scientific Advisor, Consulting fee
Amgen: Scientific Advisor, Consulting fee